Genocea Biosciences
100 Acorn Park Drive
Cambridge
Massachusetts
02140
United States
Tel: 617-876-8191
Fax: 617-876-8192
Website: http://www.genocea.com/
Email: website.inquiry@genocea.com
About Genocea Biosciences
Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases.Genocea’s pipeline includes programs addressing genital herpes, pneumococcus, chlamydia, malaria and cancer immunotherapy. We currently have two products in Phase 2 clinical development:
• GEN-003, an immunotherapy to treat patients with genital herpes. We reported positive top-line data from an ongoing Phase 2b dose optimization trial from the immediate post dosing 28-day observation period in May 2015. We identified an improved dose of 60µg per protein/75µg of adjuvant, which demonstrated a highly statistically significant reduction (p>0.0001) from baseline in the viral shedding rate (55%) and genital lesion rate (60%). Data from the six-month and 12-month observation periods in this trial is expected in the fourth quarter of 2015 and the first quarter of 2016, respectively.
Data from the prior Phase 1/2a trial was the first time a therapeutic vaccine candidate has demonstrated significant reductions in the rates of viral shedding and genital lesions in genital herpes patients.
• GEN-004, a universal vaccine which is in Phase 2 development to prevent infections caused by all serotypes of pneumococcus. We have completed enrollment in a Phase 2 human challenge clinical trial and expect to report top-line data in the fourth quarter of 2015.
In a prior Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces.
193 articles with Genocea Biosciences
-
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
9/13/2021
Genocea Biosciences, Inc. today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors.
-
Genocea to Present at Upcoming Scientific and Investor Conferences in September 2021
9/7/2021
Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.
-
Genocea Provides Second Quarter 2021 Corporate Update
7/29/2021
Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, provided a business update for the second quarter ended June 30, 2021.
-
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
7/22/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29th at 8:30 a.m. E.T.
-
Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy
7/13/2021
Genocea Biosciences, Inc. today announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 therapy. GEN-011 represents a new category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells (“NPTs”).
-
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
6/4/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), presents updated immunogenicity and clinical response data from the GEN-009 Phase 1 trial that continue to validate the company’s unique and differentiated approach to identifying clinically meaningful immunotherapy targets through the proprietary ATLAS selection process
-
Genocea Provides First Quarter 2021 Corporate Update
4/29/2021
GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens ™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) --
-
Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
4/22/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, April 29 at 8:30 a.m. ET.
-
Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021
4/10/2021
Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, presented preclinical data that offers new insights into Inhibigen™-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at the American Association for Cancer Research Annual Meeting 2021 from April 10-15.
-
Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference
4/6/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13 th at 2:15 P.M. ET.
-
Genocea to Present at the H.C. Wainwright Global Life Sciences Conference
3/2/2021
Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021.
-
Genocea Provides Fourth Quarter 2020 Corporate Update
2/11/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2020
-
Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast
2/4/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, February 11th at 8:30 a.m. ET.
-
While the ATLAS platform has the potential to lead to an effective vaccine in itself, its greatest impact in the field of immunotherapy may be that it offers a new way of understanding how a tumor evades the therapy’s boundaries by identifying bad Inhibigens that lead to suppressive, or inhibito...
-
Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
1/28/2021
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigens of anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T cell responses
-
Genocea to Participate in the B. Riley Securities’ Virtual Oncology Investor Conference
1/19/2021
Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at B. Riley Securities’ Virtual Oncology Investor Conference on January 21, 2021 from 11:00 am – 11:30 am Eastern Time. A live webcast of the fireside chat will be available on the Genocea website at http:/
-
Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
1/4/2021
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.
-
Genocea to Present at the Stifel 2020 Virtual Healthcare Conference
11/12/2020
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18th at 8:40 a.m. ET.
-
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
11/9/2020
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented four posters that collectively validate the company’s unique and differentiated approach to identifying clinically meaningful immunotherapy targets at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting taking place virtually November 9th – 14th.
-
Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast
10/22/2020
Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, October 29th at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID numb